Hydra Biosciences, a privately held biopharmaceutical company based in Cambridge, Mass., and Boehringer Ingelheim have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors for the treatment of central nervous system (CNS) diseases and disorders.

The companies will work together to identify and advance candidate inhibitors. Boehringer Ingelheim is responsible for the global development and commercialization of the inhibitors that come from the collaboration. Hydra will receive an upfront payment, additional research funding and is eligible to receive milestone payments and tiered royalty payments on future product sales.